Evaluating the stopping of medications for older adults with multiple sclerosis
Deprescribing of Disease Modifying Agents in Older Adults with Multiple Sclerosis
This study is looking at whether older adults with multiple sclerosis can safely stop taking certain medications that may not help them much anymore, to see if it makes them feel better overall.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Houston NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11078862 on NIH RePORTER |
What this research studies
This research investigates the effects of stopping Disease Modifying Agents (DMAs) in older adults with multiple sclerosis (MS), who often experience limited disease activity as they age. The study aims to assess the safety and effectiveness of discontinuing these medications, which may not provide benefits for this age group and can lead to adverse effects. By analyzing data from a large population, the research seeks to provide insights into whether older adults can safely stop taking DMAs without worsening their condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are older adults aged 65 and above who are currently taking Disease Modifying Agents for multiple sclerosis.
Not a fit: Patients under the age of 65 or those with active disease progression may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could help older adults with MS avoid unnecessary medication side effects and reduce healthcare costs.
How similar studies have performed: While some smaller studies have suggested benefits of deprescribing DMAs, this research aims to provide comprehensive data on a larger scale, making it a novel approach.
Where this research is happening
Houston, United States
- University of Houston — Houston, United States (Active)
Researchers
- Principal investigator: Aparasu, Rajender R — University of Houston
- Study coordinator: Aparasu, Rajender R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.